Roche formally activated HMRG's site on May 4, 2026 for a Phase III cardiometabolic study. Activation is the sponsor's green light to begin screening participants. It followed the on-site initiation visit completed one week earlier.
The first participant was screened the next day. By May 7, every screening slot the sponsor had allocated to the site for the month was filled. Weeks of preparation made that possible: pre-screening from our investigators' own family practices, source documents built, training complete before the notification arrived.
Screening at 304 Victoria Avenue North continues as further allocations open. Patients who want to know how joining a study at our Hamilton site works can read more before getting in touch.